573 related articles for article (PubMed ID: 15800138)
1. Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease?
Hashimoto M; Kazui H; Matsumoto K; Nakano Y; Yasuda M; Mori E
Am J Psychiatry; 2005 Apr; 162(4):676-82. PubMed ID: 15800138
[TBL] [Abstract][Full Text] [Related]
2. Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease.
Dubois B; Chupin M; Hampel H; Lista S; Cavedo E; Croisile B; Louis Tisserand G; Touchon J; Bonafe A; Ousset PJ; Ait Ameur A; Rouaud O; Ricolfi F; Vighetto A; Pasquier F; Delmaire C; Ceccaldi M; Girard N; Dufouil C; Lehericy S; Tonelli I; Duveau F; Colliot O; Garnero L; Sarazin M; Dormont D; ;
Alzheimers Dement; 2015 Sep; 11(9):1041-9. PubMed ID: 25596420
[TBL] [Abstract][Full Text] [Related]
3. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease.
Krishnan KR; Charles HC; Doraiswamy PM; Mintzer J; Weisler R; Yu X; Perdomo C; Ieni JR; Rogers S
Am J Psychiatry; 2003 Nov; 160(11):2003-11. PubMed ID: 14594748
[TBL] [Abstract][Full Text] [Related]
4. Neuroanatomical predictors of response to donepezil therapy in patients with dementia.
Csernansky JG; Wang L; Miller JP; Galvin JE; Morris JC
Arch Neurol; 2005 Nov; 62(11):1718-22. PubMed ID: 16286546
[TBL] [Abstract][Full Text] [Related]
5. Donepezil treatment and changes in hippocampal structure in very mild Alzheimer disease.
Wang L; Harms MP; Staggs JM; Xiong C; Morris JC; Csernansky JG; Galvin JE
Arch Neurol; 2010 Jan; 67(1):99-106. PubMed ID: 20065136
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of increasing donepezil in mild to moderate Alzheimer's disease patients who show a diminished response to 5 mg donepezil: a preliminary study.
Yatabe Y; Hashimoto M; Kaneda K; Honda K; Ogawa Y; Yuuki S; Ikeda M
Psychogeriatrics; 2013 Jun; 13(2):88-93. PubMed ID: 23909965
[TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease.
Bizzarro A; Marra C; Acciarri A; Valenza A; Tiziano FD; Brahe C; Masullo C
Dement Geriatr Cogn Disord; 2005; 20(4):254-61. PubMed ID: 16103669
[TBL] [Abstract][Full Text] [Related]
8. APOE-ɛ4 Carrier Status and Donepezil Response in Patients with Alzheimer's Disease.
Waring JF; Tang Q; Robieson WZ; King DP; Das U; Dubow J; Dutta S; Marek GJ; Gault LM
J Alzheimers Dis; 2015; 47(1):137-48. PubMed ID: 26402762
[TBL] [Abstract][Full Text] [Related]
9. The potentially protective effect of donepezil in Alzheimer's disease.
Ishiwata A; Mizumura S; Mishina M; Yamazaki M; Katayama Y
Dement Geriatr Cogn Disord; 2014; 38(3-4):170-7. PubMed ID: 24732387
[TBL] [Abstract][Full Text] [Related]
10. Beyond symptomatic effects: potential of donepezil as a neuroprotective agent and disease modifier in Alzheimer's disease.
Kim SH; Kandiah N; Hsu JL; Suthisisang C; Udommongkol C; Dash A
Br J Pharmacol; 2017 Dec; 174(23):4224-4232. PubMed ID: 28901528
[TBL] [Abstract][Full Text] [Related]
11. Effects of donepezil on amyloid-beta and synapse density in the Tg2576 mouse model of Alzheimer's disease.
Dong H; Yuede CM; Coughlan CA; Murphy KM; Csernansky JG
Brain Res; 2009 Dec; 1303():169-78. PubMed ID: 19799879
[TBL] [Abstract][Full Text] [Related]
12. Donepezil for severe Alzheimer's disease.
Allsop D; Martin FL; Moore S; Fullwood NJ;
Lancet; 2006 Jul; 368(9533):361; author reply 362. PubMed ID: 16876652
[No Abstract] [Full Text] [Related]
13. Do lesions involving the cortical cholinergic pathways help or hinder efficacy of donepezil in patients with Alzheimer's disease?
Fukui T; Hieda S; Bocti C
Dement Geriatr Cogn Disord; 2006; 22(5-6):421-31. PubMed ID: 16974095
[TBL] [Abstract][Full Text] [Related]
14. Vitamin E and donepezil for the treatment of mild cognitive impairment.
Petersen RC; Thomas RG; Grundman M; Bennett D; Doody R; Ferris S; Galasko D; Jin S; Kaye J; Levey A; Pfeiffer E; Sano M; van Dyck CH; Thal LJ;
N Engl J Med; 2005 Jun; 352(23):2379-88. PubMed ID: 15829527
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic evaluation of donepezil for the treatment of Alzheimer's disease.
Prvulovic D; Schneider B
Expert Opin Drug Metab Toxicol; 2014 Jul; 10(7):1039-50. PubMed ID: 24785550
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
17. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
Bullock R; Touchon J; Bergman H; Gambina G; He Y; Rapatz G; Nagel J; Lane R
Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542
[TBL] [Abstract][Full Text] [Related]
18. Disease state changes and safety of long-term donepezil hydrochloride administration in patients with Alzheimer's disease: interim results from the long-term, large-scale J-GOLD study in Japan.
Arai H; Sumitomo K; Sakata Y; Daidoji K; Takase T; Toyoda T
Psychogeriatrics; 2016 Mar; 16(2):107-15. PubMed ID: 26114729
[TBL] [Abstract][Full Text] [Related]
19. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R
Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
[TBL] [Abstract][Full Text] [Related]
20. Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy.
Modrego PJ; Fayed N; Errea JM; Rios C; Pina MA; Sarasa M
Eur J Neurol; 2010 Mar; 17(3):405-12. PubMed ID: 19874395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
